![Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database | SpringerLink Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12032-012-0286-9/MediaObjects/12032_2012_286_Fig3_HTML.gif)
Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database | SpringerLink
![Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/03ea64b3-8bc1-4956-a1fb-634144317b3c/gr1.jpg)
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry - Annals of Oncology
![Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database | SpringerLink Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12032-012-0286-9/MediaObjects/12032_2012_286_Fig1_HTML.gif)